Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.HealthLinx Expands Collaboration With Liverpool University
As per the current collaboration agreement with the University of Liverpool, HealthLinx licensed in key biomarkers that appear to have utility in the future development of OvPlex ovarian
As per the current collaboration agreement with the University of Liverpool, HealthLinx licensed in key biomarkers that appear to have utility in the future development of OvPlex ovarian
The drug delivery system contains active pharmaceutical ingredients (API). Taken orally, the wafer-thin StripTabs dissolve on the tongue immediately. This type of medication, based on a starch and
UCB, a Belgium-based biopharmaceutical company, has worked with the Department of Health to provide an alternative for people with RA through a patient access scheme. In clinical studies,
Equa, marketed as Galvus in the EU, has been approved in Japan for the treatment of type 2 diabetes, as monotherapy or in combination with a sulfonylurea. As
Reportedly, the data from phase III programs conducted in MS, were included in the applications for regulatory approval submitted to the FDA and European Medicines Agency (EMEA), in
Reportedly, as part of a 2007 suit, Johnson & Johnson has alleged that Boston Scientific’s Promus Everolimus-Eluting Coronary Stent System infringed these four patents, known as the Wright/Falotico
The authors report in the publication that the primary endpoint and key secondary endpoints of the Clarity trial were met. The Clarity data were presented at the 61st
The agreement gives Ferrer inCode, a biotech subsidiary of Grupo Ferrer Internacional, the right to sell and market ADtect initially in Germany, Belgium, the Netherlands, Luxemburg, France, Italy,
OBI-1 is indicated for the treatment of patients with acquired hemophilia and hemophilia A, who have developed an inhibitory immune reaction to human forms of factor VIII. IB1001
4SC-203 is a multi-target kinase inhibitor having selectivity profile against FLT3, FLT3 mutants and VEGF-Receptors in both in-vitro and in-vivo studies. FLT3 represents an attractive therapeutic target in